GIM
ABBV icon

Glenmede Investment Management’s AbbVie ABBV Stock Holding History

Glenmede Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$78.8M Sell
340,243
-15,663
-4% -$3.19M 0.38% 58
2025
Q2 		$66.1M Buy
+355,906
New +$66.1M 0.33% 65

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glenmede Investment Management's ABBV Position: Q3 2025 in Review

Glenmede Investment Management reduced its AbbVie (ABBV) stake by 4.4% in Q3 2025, selling an estimated $3.19M and leaving 340,243 shares worth $78.8M. The position accounts for 0.38% of the portfolio, ranked #58.

Glenmede Investment Management first reported a position in ABBV in Q2 2025 and has held it in 2 quarters since. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Glenmede Investment Management held 340,243 shares of AbbVie worth $78.8M as of Q3 2025.
  • Glenmede Investment Management sold 15,663 AbbVie shares in Q3 2025, an estimated $3.19M.
  • AbbVie made up 0.38% of Glenmede Investment Management's portfolio in Q3 2025, its #58 holding.
  • Glenmede Investment Management first reported a position in AbbVie in Q2 2025 and has held it in 2 quarters since.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.